ROCR: A Protein Linked to Cancer and Cell Proliferation (G102723505)

Target Name: ROCR

NCBI ID: G102723505

ROCR

Other Name(s): LINC02095 | regulator of chondrogenesis RNA | Regulator of chondrogenesis RNA

ROCR: A Protein Linked to Cancer and Cell Proliferation

ROCR (LINC02095) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and has been linked to a number of diseases, including cancer. As a drug target, ROCR is a promising target for the development of new treatments for a variety of diseases.

The Protein That is LINC02095

ROCR is a transmembrane protein that is composed of four distinct domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a nuclear localization domain. It has a calculated molecular weight of 118.1 kDa and a pre-fusion mass of 120 kDa. ROCR is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to play a role in regulating cell proliferation and survival.

The Role of ROCR in Cellular Proliferation

ROCR is a key regulator of cell proliferation and has been shown to play a role in the G1/S transition, which is the process by which cells prepare for cell division. During the G1/S transition, ROCR helps to regulate the levels of the protein p21, which is a key inhibitor of cell division.

In addition to its role in regulating p21 levels, ROCR has also been shown to play a role in regulating the levels of the protein p53, which is a key regulator of DNA damage repair. p53 is a protein that is often mutated in cancer and has been shown to play a role in the development of cancer. ROCR has been shown to help to regulate p53 levels, which may help to explain its role in the regulation of cell proliferation.

The link between ROCR and cancer

ROCR has been linked to a number of diseases, including cancer. For example, studies have shown that high levels of ROCR are associated with the development of breast cancer. Additionally, ROCR has been shown to be involved in the development of colon cancer, and may also play a role in the development of other cancers.

The potential uses of ROCR as a drug target

ROCR is a promising drug target due to its role in cell proliferation and its potential involvement in a variety of diseases. Studies have shown that inhibiting ROCR activity may have a variety of potential therapeutic benefits, including the treatment of cancer.

One approach to inhibiting ROCR activity is to target the extracellular domain of ROCR. This can be done using small molecules or antibodies that specifically bind to ROCR and prevent it from interacting with its downstream targets. Additionally, researchers have shown that inhibiting ROCR activity using antibodies or small molecules can cause a decrease in the levels of ROCR in cancer cells.

Another approach to inhibiting ROCR activity is to target the intracellular domain of ROCR. This can be done using drugs that specifically bind to ROCR and prevent it from interacting with its downstream targets. For example, researchers have shown that inhibiting ROCR activity using drugs that specifically bind to ROCR can cause a decrease in the levels of ROCR in cancer cells.

Conclusion

ROCR is a protein that has been shown to play a role in the regulation of cell proliferation and has been linked to a number of diseases, including cancer. As a drug target, ROCR is a promising target for the development of new treatments for a variety of diseases. In the future, researchers will continue to study the role of ROCR in cell proliferation and its potential as a drug target.

Protein Name: Regulator Of Chondrogenesis RNA

The "ROCR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ROCR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets